Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk in RV144 were measured in HVTN 702 and evaluated as correlates of HIV-1 acquisition.

Methods: Among 1893 HVTN 702 female vaccinees, 60 HIV-1-seropositive cases and 60 matched seronegative noncases were sampled. HIV-specific CD4+ T-cell and binding antibody responses were measured 2 weeks after fourth and fifth immunizations. Cox proportional hazards models assessed prespecified responses as predictors of HIV-1 acquisition.

Results: The HVTN 702 Env-specific CD4+ T-cell response rate was significantly higher than in RV144 (63% vs 40%, P = .03) with significantly lower IgG binding antibody response rate and magnitude to 1086.C V1V2 (67% vs 100%, P < .001; Pmag < .001). Although no significant univariate associations were observed between any T-cell or binding antibody response and HIV-1 acquisition, significant interactions were observed (multiplicity-adjusted P ≤.03). Among vaccinees with high IgG A244 V1V2 binding antibody responses, vaccine-matched CD4+ T-cell endpoints associated with decreased HIV-1 acquisition (estimated hazard ratios = 0.40-0.49 per 1-SD increase in CD4+ T-cell endpoint).

Conclusions: HVTN 702 and RV144 had distinct immunogenicity profiles. However, both identified significant correlations (univariate or interaction) for IgG V1V2 and polyfunctional CD4+ T cells with HIV-1 acquisition. Clinical Trials Registration . NCT02968849.

Citing Articles

Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge.

Chege G, Chapman R, Keyser A, Adams C, Benn K, van Diepen M Viruses. 2025; 17(2).

PMID: 40007032 PMC: 11861162. DOI: 10.3390/v17020277.

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Meeting summary: Global vaccine and immunization research forum, 2023.

Giersing B, Mo A, Hwang A, Baqar S, Earle K, Ford A Vaccine. 2025; 46:126686.

PMID: 39752894 PMC: 11774247. DOI: 10.1016/j.vaccine.2024.126686.

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L EClinicalMedicine. 2024; 77:102845.

PMID: 39649135 PMC: 11625018. DOI: 10.1016/j.eclinm.2024.102845.

Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines.

Lin L, Gantner P, Li S, Su B, Moog C J Infect Dis. 2024; 231(1):e1-e9.

PMID: 39302695 PMC: 11793060. DOI: 10.1093/infdis/jiae464.

References

Edlefsen P . Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis. Comput Math Methods Med. 2014; 2014:813789. PMC: 4033482. DOI: 10.1155/2014/813789. View

Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J . Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV. 2020; 7(4):e238-e248. PMC: 7247755. DOI: 10.1016/S2352-3018(19)30406-0. View

Zhao L, Fiore-Gartland A, Carpp L, Cohen K, Rouphael N, Fleurs L . Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS One. 2020; 15(1):e0226803. PMC: 6992005. DOI: 10.1371/journal.pone.0226803. View

Tomaras G, Yates N, Liu P, Qin L, Fouda G, Chavez L . Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008; 82(24):12449-63. PMC: 2593361. DOI: 10.1128/JVI.01708-08. View

Lin L, Finak G, Ushey K, Seshadri C, Hawn T, Frahm N . COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015; 33(6):610-6. PMC: 4569006. DOI: 10.1038/nbt.3187. View

Benkeser D, Carone M, van der Laan M, Gilbert P . Doubly robust nonparametric inference on the average treatment effect. Biometrika. 2018; 104(4):863-880. PMC: 5793673. DOI: 10.1093/biomet/asx053. View

Tomaras G, Haynes B . Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel). 2014; 2(1):15-35. PMC: 4053939. DOI: 10.3390/vaccines2010015. View

Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y . Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007; 323(1):39-54. PMC: 2683732. DOI: 10.1016/j.jim.2007.03.002. View

Laher F, Moodie Z, Cohen K, Grunenberg N, Bekker L, Allen M . Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020; 17(2):e1003038. PMC: 7039414. DOI: 10.1371/journal.pmed.1003038. View

10.

Silva de Castro I, Gorini G, Mason R, Gorman J, Bissa M, Rahman M . Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. iScience. 2021; 24(2):102047. PMC: 7847973. DOI: 10.1016/j.isci.2021.102047. View

11.

Fong Y, Shen X, Ashley V, Deal A, Seaton K, Yu C . Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis. 2018; 217(8):1280-1288. PMC: 6018910. DOI: 10.1093/infdis/jiy008. View

12.

Zolla-Pazner S, deCamp A, B Gilbert P, Williams C, Yates N, Williams W . Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014; 9(2):e87572. PMC: 3913641. DOI: 10.1371/journal.pone.0087572. View

13.

Hosseinipour M, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G . Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clin Infect Dis. 2020; 72(1):50-60. PMC: 7823071. DOI: 10.1093/cid/ciz1239. View

14.

Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H . Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. J Virol. 2015; 89(16):8643-50. PMC: 4524233. DOI: 10.1128/JVI.03635-14. View

15.

Gray G, Bekker L, Laher F, Malahleha M, Allen M, Moodie Z . Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021; 384(12):1089-1100. PMC: 7888373. DOI: 10.1056/NEJMoa2031499. View

16.

Tomaras G, Ferrari G, Shen X, Alam S, Liao H, Pollara J . Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013; 110(22):9019-24. PMC: 3670311. DOI: 10.1073/pnas.1301456110. View

17.

Vaccari M, Gordon S, Fourati S, Schifanella L, Liyanage N, Cameron M . Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016; 22(7):762-70. PMC: 5916782. DOI: 10.1038/nm.4105. View

18.

Tomalka J, Pelletier A, Fourati S, Latif M, Sharma A, Furr K . The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nat Immunol. 2021; 22(10):1294-1305. PMC: 8525330. DOI: 10.1038/s41590-021-01026-9. View

19.

Russell N, Marovich M . Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials. Curr Opin HIV AIDS. 2016; 11(6):614-619. DOI: 10.1097/COH.0000000000000322. View

20.

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View